Daniel Dhumeaux
Overview
Explore the profile of Daniel Dhumeaux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
3356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Delile J, de Ledinghen V, Jauffret-Roustide M, Roux P, Reiller B, Foucher J, et al.
Hepatol Med Policy
. 2018 Oct;
3:7.
PMID: 30288330
After France removed hepatitis C treatment reimbursement restrictions on 25 May 2016, an expert report presented recommendations, which focused on vulnerable groups including people who inject drugs (PWID). This commentary...
2.
Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, et al.
J Hepatol
. 2018 Sep;
69(4):785-792.
PMID: 30227916
Background & Aims: In Europe, hepatitis C virus (HCV) screening still targets people at high risk of infection. We aim to determine the cost-effectiveness of expanded HCV screening in France....
3.
Bottero J, Brouard C, Roudot-Thoraval F, Deuffic-Burban S, Hofliger P, Abergel A, et al.
Liver Int
. 2016 Apr;
36(10):1442-9.
PMID: 27043826
Background & Aims: Worldwide and, to a lesser extent, in France, a minority of individuals infected with hepatitis B (HBV) and C (HCV) is aware of its status. Given the...
4.
Erlinger S, Arias I, Dhumeaux D
Gastroenterology
. 2014 Apr;
146(7):1625-38.
PMID: 24704527
Inherited disorders of bilirubin metabolism might reduce bilirubin uptake by hepatocytes, bilirubin conjugation, or secretion of bilirubin into bile. Reductions in uptake could increase levels of unconjugated or conjugated bilirubin...
5.
Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux G, et al.
J Hepatol
. 2014 Mar;
61(1):7-14.
PMID: 24650691
Background & Aims: In treatment-naive patients mono-infected with genotype 1 chronic HCV, treatments with telaprevir/boceprevir (TVR/BOC)-based triple therapy are standard-of-care. However, more efficacious direct-acting antivirals (IFN-based new DAAs) are available...
6.
Feray C, Pawlotsky J, Roque-Afonso A, Samuel D, Dhumeaux D
Lancet
. 2014 Jan;
383(9913):218.
PMID: 24439737
No abstract available.
7.
Dhumeaux D, Erlinger S
J Hepatol
. 2012 Sep;
58(2):388-90.
PMID: 22982575
Bilirubin, a breakdown product of heme, is normally glucuronidated and excreted by the liver into bile. Failure of this system can lead to a buildup of conjugated bilirubin in the...
8.
Chouteau P, Defer N, Florimond A, Calderaro J, Higgs M, Gaudin A, et al.
J Hepatol
. 2012 May;
57(3):499-507.
PMID: 22613003
Background & Aims: During chronic HCV infection, activation of fibrogenesis appears to be principally related to local inflammation. However, the direct role of hepatic HCV protein expression in fibrogenesis remains...
9.
Deuffic-Burban S, Mathurin P, Pol S, Larsen C, Roudot-Thoraval F, Desenclos J, et al.
Gut
. 2011 Sep;
61(2):290-6.
PMID: 21930731
Objective: The combination of pegylated interferon (PEG-IFN), ribavirin (RBV) and a protease inhibitor (PI) has been approved in summer 2011 for the treatment of genotype 1 (G1) hepatitis C virus...
10.
Hezode C, Chevaliez S, Bouvier-Alias M, Roudot-Thoraval F, Brillet R, Zafrani E, et al.
J Hepatol
. 2007 Feb;
46(5):791-6.
PMID: 17321635
Background/aims: Some patients receiving adefovir at the approved dose of 10 mg daily for chronic hepatitis B have a "suboptimal" virological response characterized by a slow and moderate decrease in...